Empatica, a leader in digital biomarker development, has partnered with Mobilise-D, an initiative funded by the Innovative Medicines Initiative. This collaboration aims to integrate Mobilise-D’s Digital Mobility Outcomes (DMOs) into Empatica’s Health Monitoring Platform.
DMOs are validated digital measures that assess mobility using wearable sensors. By integrating these outcomes into its platform, Empatica provides researchers and clinicians with a comprehensive tool for monitoring mobility in patients with Parkinson’s, COPD, and multiple sclerosis.
This partnership removes barriers to implementing digital outcomes in clinical trials by seamlessly providing accurate and reliable data. Empatica’s EmbracePlus wearable and Health Monitoring Platform consolidates advanced mobility analytics with Empatica’s robust technology.
The collaboration aims to drive innovation and harmonize digital outcome assessment in clinical trials. By combining Mobilise-D’s algorithms with Empatica’s technology, researchers can easily include these measures in studies, reducing participant burden.
Integrating Mobilise-D DMOs into Empatica’s platform is a significant step toward regulatory approval of digital endpoints in clinical drug development. It enables the assessment of mobility in daily life, aiding therapeutic development and precision medicine.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.